Noninvasive Markers of Liver Fibrosis and Inflammation in Chronic Hepatitis B-Virus Related Liver Disease

Mohamadnejad, Mehdi; Montazeri, Ghodratollah; Fazlollahi, Atoosa; Zamani, Farhad; Nasiri, Jafar; Nobakht, Hossein; Forouzanfar, Mohammad H.; Abedian, Shifteh; Tavangar, Seyed Mohammad; Ashraf, Muhammad; Ghoujeghi, Farhad; Estakhri, Arezoo; Nouri, Negin; Farzadi, Zahra; Najjari, Abolfazl; Malekzadeh, Reza

doi:10.1111/j.1572-0241.2006.00788.x

Cited by 93 publications

(87 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These tests, called multianalyte assays with algorithmic analyses (MAAAs), based on correlating and normalizing multiple sets of variables, are increasing in usage and show applicability in many diseases. FibroSure (FibroTest), for example, is a six-panel blood test for liver damage which has become widely used for hepatitis C diagnosis and detection and can replace liver biopsy [33,34]. MammaPrint, a 70-gene assay test for metastatic breast cancer, was FDA approved in 2007.…”

Section: Multianalyte Assays With Algorithm Analysesmentioning

confidence: 99%

Neuroendocrine Tumor Biomarkers: Current Status and Perspectives

et al. 2014

View full text Add to dashboard Cite

The identification of accurate harbingers of disease status and therapeutic efficacy are critical requirements in precise diagnosis and effective management. Initially, tissue analysis was regarded as ideal but invasive strategies represent risk compared with peripheral blood sampling. Thus far, most biomarkers, whether in tissue or blood/urine, have been single analytes with varying degrees of sensitivity and specificity. Some analytes have not exhibited robust metrics or have lacked methodological rigor. Neuroendocrine disease represents an area of dire biomarker paucity since the individual biomarkers (gastrin, insulin, etc.) are not widely applicable to the diverse types of neuroendocrine neoplasia. Broad-spectrum markers such as chromogranin A have limitations in sensitivity, specificity and reproducibility. Monoanalytes cannot define the multiple variables (proliferation, metabolic activity, invasive potential, metastatic propensity) that constitute tumor growth. The restricted status of the neuroendocrine neoplasia field has resulted in a lack of comprehensive knowledge of the molecular and cellular biology of the disease, with tardy application of innovative technology. This overview examines limitations in current practice and describes contemporary viable strategies under evaluation, including the identification of novel analytes (gene transcripts, microRNA), circulating tumor cells and metabolic imaging agents that identify disease. Novel requirements are necessary to develop biomathematical algorithms for synchronous calibration of multiple molecular markers and predictive nomograms that interface biological variables to delineate disease progress or treatment efficacy. Optimally, the application of novel techniques and amalgamations of multianalyte assessment will provide a personalized molecular disease signature extrapolative of neuroendocrine neoplasia status and likelihood of progression and predictive of therapeutic opportunity.

show abstract

Section: Multianalyte Assays With Algorithm Analysesmentioning

confidence: 99%

Neuroendocrine Tumor Biomarkers: Current Status and Perspectives

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Liver biopsy is considered to be a gold standard to establish the precise diagnosis of liver cirrhosis. However, it is an invasive procedure, and small biopsies are more prone to sampling error [19,20]. Although all of the cases in our studies were confirmed by liver biopsy, it was very difficult to repeat the liver biopsy for follow up in these patients.…”

Section: Discussionmentioning

confidence: 64%

Correlation between viral load and liver cirrhosis in chronic hepatitis B patients

2009

View full text Add to dashboard Cite

The aim of this paper is to investigate the relationship between hepatitis B virus (HBV) DNA levels during the course and the progression to cirrhosis with chronic hepatitis B. A total of 239 chronic hepatitis B patients confirmed by liver biopsy between 2001 and 2007 were followed up for a median of 28 months. Compared with the patients without cirrhosis, the patients progressed to cirrhosis were older and with higher HBV-DNA levels at end point. However, there was no significant difference in cirrhosis progression between different HBV-DNA groups at baseline (P = 0.531). Kaplan-Meier analysis showed higher HBV-DNA level at endpoint had increasing risk of cirrhosis (P = 0.019). The results of Cox model indicated that HBV-DNA levels at endpoint, stage of fibrosis, negative hepatitis B e antigen, and γ-glutamyl transpeptidase at baseline were independent risk factors of cirrhosis. The relative risk ratios were 1.898, 1.918, 8.976, and 1.006, respectively. Progression to cirrhosis in chronic hepatitis B patients is correlated with HBV-DNA levels during follow-up.

show abstract

“…Assessment of liver fibrosis with multiple serum markers used in combination is sensitive, specific, and reproducible, suggesting that multiple serum markers may be used in conjunction with liver biopsy to assess a range of chronic liver diseases. Recently, algorithms and indices using clinical and biochemical measurements have been advanced as methods for detecting liver fibrosis in chronic hepatitis C [9,12,14,15,18], and current noninvasive scores give reliable information on liver fibrosis in one-third of patients with chronic hepatitis C, especially when used in combination; however, there are insufficient reports in patients with chronic hepatitis B [13,17,19].…”

Section: Introductionmentioning

confidence: 99%

Non-Invasive Index for Predicting Significant Liver Fibrosis: Comparison of Diagnostic Performances in Patients with Chronic Hepatitis B and C

Cheong

Seo

et al. 2010

Dig Dis Sci

View full text Add to dashboard Cite

Background/Aims The majority of non-invasive markers of liver fibrosis have been developed in patients with chronic hepatitis C. We aimed to develop a formula for predicting significant fibrosis in patients with chronic viral hepatitis and to compare the usefulness of published models derived from the data obtained from patients with chronic hepatitis C. Methods Serum markers and the METAVIR stage of fibrosis in liver biopsy specimens were compared prospectively in patients with chronic hepatitis B and C (estimation set, 367; validation set, 159). Results In the estimation set, multiple forward stepwise logistic regression analysis identified c-glutamyl transpeptidase, haptoglobin, a2-macroglobulin, matrix metalloproteinase-2, and tissue inhibitor of metalloproteinase-1 as independent predictors of significant fibrosis. A formula termed the SF index was constructed with the aforementioned five variables. The areas under the receiver operating characteristic curves of the SF index for predicting significant fibrosis were 0.828, 0.776, and 0.827 in the estimation, validation, and total sets, respectively. Using cut-off scores of 2.2 and 3.3, significant fibrosis was predicted with considerable accuracy. The diagnostic performances of the SF index and the Zeng index derived from chronic hepatitis B patients were much better than indices derived from chronic hepatitis C patients, such as the APRI, Forns index, and FIB-4. Conclusions We developed a novel formula for predicting significant fibrosis in patients with chronic viral hepatitis. Serum indices from studies in patients with chronic hepatitis C were less accurate in patients with chronic hepatitis B for predicting significant fibrosis.

show abstract

Noninvasive Markers of Liver Fibrosis and Inflammation in Chronic Hepatitis B-Virus Related Liver Disease

Abstract: Significant hepatic fibrosis and necroinflammation can reliably be predicted using routinely checked tests and HBV DNA levels.

Cited by 93 publications

References 26 publications

Neuroendocrine Tumor Biomarkers: Current Status and Perspectives

Neuroendocrine Tumor Biomarkers: Current Status and Perspectives

Correlation between viral load and liver cirrhosis in chronic hepatitis B patients

Non-Invasive Index for Predicting Significant Liver Fibrosis: Comparison of Diagnostic Performances in Patients with Chronic Hepatitis B and C

Contact Info

Product

Resources

About